All data is delayed
See More

Aspen unit to buy drug portfolio from GSK

Aug 15 2012 08:53

Company Data


Last traded 307
Change 2
% Change 1
Cumulative volume 716757
Market cap 0

Last Updated: 21-10-2016 at 12:38. Prices are delayed by 15 minutes. Source: McGregor BFA

Related Articles

Drug firms win R2.5bn tender

Pfizer pulls false Centrum vitamin claims

Adcock buys Indian medicine business

Fake Grand-Pas pulled from shelves

Aspen buys GSK brands

Aspen prepared to help bridge ARV shortages

Johannesburg - Aspen Pharmacare [JSE:APN] said on Wednesday its subsidiary, Aspen Global, will pay £172m for GlaxoSmithKline's pharmaceutical products distributed in Australia.

Aspen said in a statement that the purchase price for the 25 pharmaceutical products was subject to a small reduction should the deal not be completed by October 31.

It said the deal will be funded from new offshore debt facilities and that Aspen Australia was expected to distribute the products.

The deal was subject to regulatory approvals from Australian authorities, the company said.

Aspen also announced in April that it would pay $263m for GSK's international over-the-counter brands.
aspen  |  glaxosmithkline  |  drugs


Read Fin24’s Comments Policy publishes all comments posted on articles provided that they adhere to our Comments Policy. Should you wish to report a comment for editorial review, please do so by clicking the 'Report Comment' button to the right of each comment.

Comment on this story
Comments have been closed for this article.

Company Snapshot

Money Clinic

Money Clinic
Do you have a question about your finances? We'll get an expert opinion.
Click here...

Voting Booth

Do you use all your downloaded apps on your smartphone?

Previous results · Suggest a vote